Cargando…

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis

Endometriosis is a common, benign, and hormone-dependent gynaecological disorder that displays altered immunoinflammatory profiles. Myeloid-derived suppressor cells (MDSCs) suppressed immunosurveillance in endometriosis in human and mouse model. Receptor tyrosine kinase inhibitor Sunitinib can induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Ying, Hung, Sze Wan, Liang, Bo, Zhang, Ruizhe, Gao, Yating, Chu, Ching Yan, Zhang, Tao, Xu, Hui, Chung, Jacqueline Pui Wah, Wang, Chi Chiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340010/ https://www.ncbi.nlm.nih.gov/pubmed/34367125 http://dx.doi.org/10.3389/fimmu.2021.641206

Ejemplares similares

Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review
por: Hung, Sze Wan, et al.
Publicado: (2021)

Re-evaluation of mouse models of endometriosis for pathological and immunological research
por: He, Ying, et al.
Publicado: (2022)

An In-Silico, In-Vitro and In-Vivo Combined Approach to Identify NMNATs as Potential Protein Targets of ProEGCG for Treatment of Endometriosis
por: Hung, Sze Wan, et al.
Publicado: (2021)

Melatonin in Endometriosis: Mechanistic Understanding and Clinical Insight
por: Li, Yiran, et al.
Publicado: (2022)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Endometrial Vascularization Characterized by Optical Coherence Tomography and Immunohistochemistry in Women Undergoing In Vitro Fertilization-Embryo Transfer Treatment
por: Law, Tracy Sze Man, et al.
Publicado: (2019)

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)

Effective Antiviral Activity of the Tyrosine Kinase Inhibitor Sunitinib Malate against Zika Virus
por: Lin, Chen-Sheng, et al.
Publicado: (2021)

Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib
por: Shen, Li, et al.
Publicado: (2019)

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
por: Bernard, Valérie, et al.
Publicado: (2016)

Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
por: Wang, Yufei, et al.
Publicado: (2020)

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2021)

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer
por: Brooks, Colin, et al.
Publicado: (2012)

Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
por: Sourdon, Joevin, et al.
Publicado: (2017)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in the Development and/or Progression of Endometriosis-State of the Art
por: Suszczyk, Dorota, et al.
Publicado: (2021)

Correction to: Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2022)

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
por: Qin, Guohui, et al.
Publicado: (2023)

Differential Effects of Tyrosine Kinase Inhibitors on Volume-sensitive Chloride Current in Human Atrial Myocytes: Evidence for Dual Regulation by Src and EGFR Kinases
por: Du, Xin-Ling, et al.
Publicado: (2004)

Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
por: Knoerzer, D, et al.
Publicado: (2013)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
por: Sbitti, Yassir, et al.
Publicado: (2018)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Metastatic Perivascular Epithelioid Cell Tumor Of The Kidney: A Case Report With Emphasis On Response To The Tyrosine-Kinase Inhibitor Sunitinib
por: AlAzab, Rami S, et al.
Publicado: (2019)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment
por: Gao, Xidan, et al.
Publicado: (2021)

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
por: Draghiciu, Oana, et al.
Publicado: (2015)

What We Have Learned from Animal Models to Understand the Etiology and Pathology of Endometrioma-Related Infertility
por: Tan, Zhouyurong, et al.
Publicado: (2022)

Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy
por: He, Wei, et al.
Publicado: (2016)

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2
por: Jiménez-Izquierdo, Rafael, et al.
Publicado: (2023)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo
por: Jensen, Brian C., et al.
Publicado: (2017)

Immunology and Immunotherapy of Endometriosis
por: Maksym, Radosław B., et al.
Publicado: (2021)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
por: Petrazzuolo, Adriana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oge7q0k4ekr81ru4iqcr9v9pgr